Condition: Gynecologic Cancers · Platinum-Sensitive Ovarian Cancer · Fallopian Tube Cancer · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. P…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Holy Name Medical Center /ID# 279017 | Teaneck, New Jersey, United States | Recruiting |
| University of Cincinnati Medical Center. /ID# 278925 | Cincinnati, Ohio, United States | Recruiting |
| OU Health - Stephenson Cancer Center /ID# 277656 | Oklahoma City, Oklahoma, United States | Recruiting |
| Providence Portland Medical Center /ID# 277727 | Portland, Oregon, United States | Recruiting |
| Women & Infants Hospital /ID# 277930 | Providence, Rhode Island, United States | Recruiting |
| SCRI Oncology Partners /ID# 279733 | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology-Austin North /ID# 279958 | Austin, Texas, United States | Recruiting |
| Next Virginia /ID# 279684 | Fairfax, Virginia, United States | Recruiting |
| Rabin Medical Center /ID# 279142 | Petah Tikva, Central District, Israel | Recruiting |
| The Chaim Sheba Medical Center /ID# 275997 | Ramat Gan, Tel Aviv, Israel | Recruiting |
| Tel Aviv Sourasky Medical Center /ID# 275852 | Tel Aviv, Tel Aviv, Israel | Recruiting |
| Rambam Health Care Campus- Haifa /ID# 276004 | Haifa, Israel | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07024784